Noah Merin, MD, PhD

Dr. Chaudhary and Dr. Merin discuss potential areas for exploration and unmet needs in the chronic GvHD treatment landscape.

Discussion centered around real-world data following the approval of ruxolitinib as a treatment option for patients with chronic GvHD as well as discussing treatment selection for patients with chronic GvHD, with special consideration for treatment sequencing.

A brief review of the key efficacy data for two treatment options, Ibrutinib and Belumosudil, in patients with chronic GvHD.

Dr. Merin describes the mechanisms of action of ruxolitinib, ibrutinib, and belumosudil and shares clinical pearls for community oncologists on methods for achieving response with these agents.

Dr. Chaudhary introduces data supporting the use of ruxolitinib as a first-line option in patients with steroid-refractory chronic GvHD.

Dr. Merin defines steroid refractory chronic GvHD, explains how to determine when patients become steroid-refractory and discusses treatment approach for this population.

Expert clinicians discuss first-line treatment methodologies for chronic GvHD, with a focus on tailoring treatments to the patient.

Preet M. Chaudhary, MD, PhD and Noah Merin, MD, PhD review how chronic GvHD is diagnosed, the different types of chronic GvHD, and key risk factors for the disease.